June 18, 2020 / 1:48 PM / 21 days ago

BRIEF-Abbvie Says RINVOQ Monotherapy Shows Improvement In Skin Clearance And Itch In First Phase 3 Study

June 18 (Reuters) - Abbvie Inc:

* RINVOQ™ (UPADACITINIB) MONOTHERAPY SHOWS IMPROVEMENT IN SKIN CLEARANCE AND ITCH IN FIRST PHASE 3 STUDY FOR ATOPIC DERMATITIS

* ABBVIE - NO NEW SAFETY RISKS OBSERVED VERSUS SAFETY PROFILE OBSERVED IN PATIENTS WITH RHEUMATOID ARTHRITIS & PSORIATIC ARTHRITIS RECEIVING RINVOQ

* ABBVIE - IN STUDY, MOST COMMON TREATMENT-EMERGENT ADVERSE EVENTS WERE ACNE, UPPER RESPIRATORY TRACT INFECTION & NASOPHARYNGITIS

* ABBVIE - BOTH DOSES OF UPADACITINIB (15 MG & 30 MG) MONOTHERAPY MET ALL PRIMARY & SECONDARY ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below